Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end.
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Servier to buy Edgewise Therapeutics' muscular dystrophy drug
Servier buys into muscular dystrophy with potentially $2.7B deal
This Biotech Snatched Up $1.55 Billion And Removed A Key Overhang
Le laboratoire Servier mise 1,33 milliard d’euros sur des traitements contre les dystrophies musculaires
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion…
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could…
Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business.
Le groupe pharmaceutique français rachète l’activité dystrophie musculaire de l’américain Edgewise Therapeutics, incluant un…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Cartesian’s $150M financing; Editas Medicine’s money moves
